CA2710223A1 - Treatment of surgical adhesions - Google Patents

Treatment of surgical adhesions Download PDF

Info

Publication number
CA2710223A1
CA2710223A1 CA2710223A CA2710223A CA2710223A1 CA 2710223 A1 CA2710223 A1 CA 2710223A1 CA 2710223 A CA2710223 A CA 2710223A CA 2710223 A CA2710223 A CA 2710223A CA 2710223 A1 CA2710223 A1 CA 2710223A1
Authority
CA
Canada
Prior art keywords
connexin
agent
seq
peptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2710223A
Other languages
English (en)
French (fr)
Inventor
Bradford J. Duft
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inflammx Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2710223A1 publication Critical patent/CA2710223A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/25—Peptides having up to 20 amino acids in a defined sequence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Surgery (AREA)
  • Cell Biology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CA2710223A 2007-12-21 2008-12-22 Treatment of surgical adhesions Abandoned CA2710223A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US888807P 2007-12-21 2007-12-21
US61/008,888 2007-12-21
PCT/US2008/014019 WO2009085268A2 (en) 2007-12-21 2008-12-22 Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions

Publications (1)

Publication Number Publication Date
CA2710223A1 true CA2710223A1 (en) 2009-07-09

Family

ID=40824953

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2710223A Abandoned CA2710223A1 (en) 2007-12-21 2008-12-22 Treatment of surgical adhesions

Country Status (7)

Country Link
US (1) US20110245184A1 (enExample)
EP (1) EP2237796A2 (enExample)
JP (2) JP2011507855A (enExample)
AU (1) AU2008343839A1 (enExample)
CA (1) CA2710223A1 (enExample)
WO (1) WO2009085268A2 (enExample)
ZA (1) ZA201005215B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2596412A1 (en) 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
CN101970663A (zh) * 2007-12-11 2011-02-09 科达治疗公司 受损伤口愈合的组合物和治疗
WO2009085270A2 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions
RU2657535C2 (ru) 2012-03-01 2018-06-14 Ферстстринг Рисерч, Инк. Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act)
US9156896B2 (en) * 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
EP3116996A4 (en) * 2014-03-14 2018-01-10 Ocunexus Therapeutics, Inc. Treatment of resistant lesions
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
CN105566495B (zh) * 2016-01-27 2019-10-22 上海科技大学 一种特异性抑制连接蛋白26的全人抗体
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
CA3196342A1 (en) 2020-10-22 2022-04-28 Gautam Ghatnekar Peptide formulations and ophthalmic uses thereof
JP6911993B1 (ja) * 2020-12-11 2021-07-28 東洋インキＳｃホールディングス株式会社 抗菌性活性エネルギー線硬化型コーティング組成物、コーティング層、抗菌性部材、および物品

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1146908E (pt) * 1999-01-27 2005-10-31 David Dr Becker Formulacoes que contem nucleotidos de anti-sentido para conexinas
CA2461542A1 (en) * 2001-10-17 2003-04-24 Tudor Morley Griffith Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
WO2006006948A2 (en) * 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
EP2289535B8 (en) * 2004-12-21 2018-08-08 MUSC Foundation for Research Development Compositions and methods for promoting wound healing and tissue regeneration
CA2596412A1 (en) * 2005-02-03 2006-12-21 Coda Therapeutics Limited Anti-connexin compounds and uses thereof
KR20150072458A (ko) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. 상처 치유를 위한 개선 방법 및 조성물
JP2011506446A (ja) * 2007-12-11 2011-03-03 コーダ セラピューティクス， インコーポレイテッド 損傷した創傷治癒組成物および治療
CN101970663A (zh) * 2007-12-11 2011-02-09 科达治疗公司 受损伤口愈合的组合物和治疗

Also Published As

Publication number Publication date
EP2237796A2 (en) 2010-10-13
WO2009085268A2 (en) 2009-07-09
JP2014208699A (ja) 2014-11-06
ZA201005215B (en) 2011-06-29
WO2009085268A3 (en) 2009-10-01
US20110245184A1 (en) 2011-10-06
JP2011507855A (ja) 2011-03-10
AU2008343839A1 (en) 2009-07-09

Similar Documents

Publication Publication Date Title
US20110245184A1 (en) Treatment of surgical adhesions
CA2710232A1 (en) Treatment of abnormal or excessive scars
US20110092449A1 (en) Treatment of fibrotic conditions
US20110243964A1 (en) Treatment of orthopedic conditions
US9738892B2 (en) Treatment of fibrotic conditions
US20100279921A1 (en) Impaired wound healing compositions and treatments
EP2238250B1 (en) Use of anti-connexin 43 polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
US20110144182A1 (en) Treatment of surgical adhesions
EP2252690A2 (en) Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2015201305A1 (en) Treatment of fibrotic conditions
AU2015201309A1 (en) Treatment of fibrotic conditions

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131220

FZDE Discontinued

Effective date: 20161214